Hans-Joachim Paust

TL;DR: Targeting the IL-23/IL-17 axis may be a promising therapeutic strategy for the treatment of proliferative and crescentic glomerulonephritis.

TL;DR: Data suggest that CCR6 mediates renal recruitment of both T Regs and Th17 cells and that the reduction of anti-inflammatory Tregs in the presence of a fully functional Th1 response aggravates experimental glomerulonephritis.

TL;DR: For the first time, a beneficial effect of CXCR3 deficiency is demonstrated through attenuation of both the Th1 and the newly defined Th17 immune response, identifying the chemokine receptor CX CR3 as a promising therapeutic target in lupus nephritis.

TL;DR: The potential role of the Th17 immune response in human and experimental renal inflammation with a special focus on glomerulonephritis is discussed, including the identification and characterization of IL-17-producing T cells in nephritic kidneys of mice and humans, as well as evidence for the contribution of IL

TL;DR: Depletion of intestinal Th17 cells in germ-free and antibiotic-treated mice ameliorated renal disease, whereas expansion of these cells upon Citrobacter rodentium infection exacerbated pathology.